PFIZER has announced the cessation of R&D programs focused on early stage drugs for neuroscience, including Alzheimer's and Parkinson's disease.
About 300 US jobs will be impacted by the change which follows a review of operations to ensure the company is "in the strongest possible position to support scientific discovery and development," with funds redirected to areas where Pfizer has "strong scientific leadership".
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jan 18
